{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:18:08Z","timestamp":1790281088445,"version":"4.1.0"},"reference-count":61,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","award":["RT\u20102020\u20100516"],"award-info":[{"award-number":["RT\u20102020\u20100516"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J intellect Disabil Res"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>People with intellectual\/developmental disabilities (IDD) are known to have high rates of prescription drug use, particularly for psychotropic medications. This is of concern due to the many side effects associated with these medications and because of the risks of polypharmacy. In this paper we compare the most commonly dispensed drugs and all psychotropic medications for youth with IDD compared with youth without IDD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using population\u2010level administrative health data over a 10\u2010year period, this study examined medications dispensed to youth with an IDD aged 15\u201324\u00a0years compared with youth without an IDD. The most common medications dispensed and the number of youth they were dispensed to were determined. As well a wide variety of psychotropic medications were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were a total of 20\u00a0591 youth with IDD and 1\u00a0293\u00a0791 youth without IDD identified. Youth with IDD had higher odds of being dispensed pain medications, amoxicillin, salbutamol, levothyroxine and all the psychotropic medications (antidepressants, antipsychotics, anxiolytics, anti\u2010adrenergic agents, mood stabilisers and stimulants). For youth with IDD, 6558 (31.85%) were dispensed two or more different psychotropic medications within a year, compared with 75\u00a0963 (5.87%) of youth without IDD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Compared to youth without IDD, youth with IDD had significantly higher odds of being dispensed most of the prescription medications studied, including all of the psychotropic medications. They were also twice as likely to be dispensed two or more medications from different classes of psychotropic drugs within the same year. These findings have important implications for the health of people with IDD and for their health care providers.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jir.13147","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T06:06:11Z","timestamp":1716357971000},"page":"1156-1166","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A retrospective cohort study of prescription drug use among youth with intellectual\/developmental disabilities in British Columbia"],"prefix":"10.1111","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-3556","authenticated-orcid":false,"given":"S.","family":"Marquis","sequence":"first","affiliation":[{"name":"School of Nursing, Faculty of Applied Science University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. E.","family":"Marquis","sequence":"additional","affiliation":[{"name":"No affiliation  Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1866-9728","authenticated-orcid":false,"given":"Y.","family":"Lunsky","sequence":"additional","affiliation":[{"name":"Azrieli Adult Neurodevelopmental Centre Campbell Family Mental Health Research Institute, CAMH  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"McGrail","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Policy Research The University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Baumbusch","sequence":"additional","affiliation":[{"name":"School of Nursing, Faculty of Applied Science University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01183-1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.12688\/hrbopenres.13599.1"},{"key":"e_1_2_11_4_1","first-page":"36","article-title":"Prevalence of thyroid dysfunctions in infants and children with Down Syndrome (DS) and the effect of thyroxine treatment on linear growth and weight gain in treated subjects versus DS subjects with normal thyroid function: A controlled study","volume":"90","author":"AlAaraj N.","year":"2019","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.23889\/ijpds.v4i2.1133"},{"key":"e_1_2_11_6_1","unstructured":"ATC\/DDD Index2023(2023)World Health Organization Centre for Drug Statistics Methodology. Available at:https:\/\/www.whocc.no\/atc_ddd_index\/(Accessed: 6 October 2023)."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199218"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02238.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rasd.2020.101642"},{"key":"e_1_2_11_10_1","unstructured":"British Columbia Ministry of Health [creator](2020):Medical Services Plan (MSP) payment information file. V2 population data BC [publisher]. Data extract. MOH (2021). (no date). Available at:http:\/\/www.popdata.bc.ca\/data."},{"key":"e_1_2_11_11_1","unstructured":"British Columbia Ministry of Health [creator](2021a):Consolidation file (MSP registration and premium billing). V2. Population data BC [publisher]. Data extract. MOH (2021). (2021). Available at:http:\/\/www.popdata.bc.ca\/data."},{"key":"e_1_2_11_12_1","unstructured":"British Columbia Ministry of Health [creator](2021b):PharmaNet. V2. Population data BC [publisher]. Data extract. Data Stewardship Committee (2021). (no date). Available at:http:\/\/www.popdata.bc.ca\/data."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.10.096"},{"key":"e_1_2_11_14_1","article-title":"Antipsychotic medication for challenging behaviour in people with learning disability","volume":"3","author":"Brylewski J.","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_11_15_1","unstructured":"Canadian Institute for Health Information [creator](2020and 2021):Discharge abstract database (hospital separations). V2 population data BC [publisher]. Data extract. MOH (2021). (no date). Available at:http:\/\/www.popdata.bc.ca\/data."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2012.02.009"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2010.01275.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/19315864.2023.2192691"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2017.04.002"},{"key":"e_1_2_11_20_1","first-page":"124","article-title":"Substance use disorders in people with intellectual disability","volume":"32","author":"Didden R.","year":"2019","journal-title":"Current Opinion in Psychiatry"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3484"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-035280"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-023-00526-w"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12461"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2022.612"},{"key":"e_1_2_11_26_1","volume-title":"Aripiprazole for Autism Spectrum Disorders (ASD), Cochrane Database of Systematic Reviews","author":"Hirsch L. E.","year":"2016"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-407760-7.00001-3"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2104"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12100"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031210-100700"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mrdd.20098"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12002"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011638"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2011.10.007"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717727240"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jar.12698"},{"key":"e_1_2_11_37_1","first-page":"2","article-title":"Population level mental health diagnoses for youth with intellectual\/developmental disabilities compared to youth without intellectual\/developmental disabilities","author":"Marquis S.","year":"2024","journal-title":"Research on Child and Adolescent Psychopathology"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2023.101478"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2006.04.002"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796018000604"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900465"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107940"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/jar.12580"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bld.12206"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.2003.00511.x"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12391"},{"key":"e_1_2_11_47_1","first-page":"291","article-title":"Evaluating and managing irritability and aggression in children and adolescents with autism spectrum disorder: an algorithm","volume":"65","author":"Ooi A.","year":"2023","journal-title":"British Columbia Medical Journal"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/2955772"},{"key":"e_1_2_11_49_1","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists. Evidence\u2010based clinical practice guidelines","volume":"64","author":"Pottie K.","year":"2018","journal-title":"Canadian Family Physician"},{"key":"e_1_2_11_50_1","unstructured":"Government of Canada(2022).Ranitidine products recalled because of a nitrosamine impurityAvailable at:https:\/\/recalls\u2010rappels.canada.ca\/en\/alert\u2010recall\/ranitidine\u2010products\u2010recalled\u2010because\u2010nitrosamine\u2010impurity(Accessed: 8 November 2023)."},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4326"},{"key":"e_1_2_11_52_1","unstructured":"SAS Institute Inc. (n.d.)Statistical Analysis System version 9.4SAS Institute Inc. Cary NC USA."},{"key":"e_1_2_11_53_1","unstructured":"Statistics Canada(2009):Statistics Canada income band data. Catalogue bumber: 13C0016. V2. Population data BC. Data extract. Population data BC (2021)(no date). Available at:http:\/\/www.popdata.bc.ca\/data."},{"key":"e_1_2_11_54_1","unstructured":"Government of Canada(2020).Status of ranitidine drugs in CanadaAvailable at:https:\/\/recalls\u2010rappels.canada.ca\/en\/alert\u2010recall\/status\u2010ranitidine\u2010drugs\u2010canada(Accessed: 8 November 2023)."},{"key":"e_1_2_11_55_1","unstructured":"NHS England(n.d.).Stopping over\u2010medication of people with a learning disability autism or bothAvailable at:https:\/\/www.england.nhs.uk\/wp\u2010content\/uploads\/2017\/07\/stomp\u2010gp\u2010prescribing\u2010v17.pdf."},{"key":"e_1_2_11_56_1","first-page":"254","article-title":"Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines","volume":"64","author":"Sullivan W. F.","year":"2018","journal-title":"Canadian Family Physician"},{"key":"e_1_2_11_57_1","first-page":"S30","article-title":"Supporting adults with intellectual and developmental disabilities to cope and thrive through transitions to later\u2010life phases","volume":"65","author":"Sullivan W. F.","year":"2019","journal-title":"Canadian Family Physician"},{"key":"e_1_2_11_58_1","doi-asserted-by":"crossref","unstructured":"Down Syndrome Medical Interest Group (DSMIG) UK & Ireland(2020)Thyroid disorder in children and young people with Down syndrome. Surveillance and when to initiate treatmentwww.dsmig.org.uk\/wp\u2010content\/uploads\/2020\/04\/FINAL_Thyroid\u2010Disorder\u2010in\u2010Down\u2010Syndrome\u2010Guideline\u2010with\u2010all\u2010logos\u2010v7.1_230420.pdf.","DOI":"10.1136\/archdischild-2020-321080"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7750(06)33002-9"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-022-00418-x"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7728"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000525988"}],"container-title":["Journal of Intellectual Disability Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jir.13147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T10:00:31Z","timestamp":1732096831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jir.13147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/jir.13147"],"URL":"https:\/\/doi.org\/10.1111\/jir.13147","archive":["Portico"],"relation":{},"ISSN":["0964-2633","1365-2788"],"issn-type":[{"value":"0964-2633","type":"print"},{"value":"1365-2788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"2024-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}